Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

BACKGROUND: Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). This study assesses adherence and duration of therapy with FTD + TPI versus REG and explores the effect of sequencing on adherence. MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Anuj K., Barghout, Victoria, Yenikomshian, Mihran A., Germain, Guillaume, Jacques, Philippe, Laliberté, François, Duh, Mei S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964129/
https://www.ncbi.nlm.nih.gov/pubmed/31591140
http://dx.doi.org/10.1634/theoncologist.2019-0240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964129/
https://www.ncbi.nlm.nih.gov/pubmed/31591140
http://dx.doi.org/10.1634/theoncologist.2019-0240

Ejemplares similares